Merck and ChemLex have agreed on a collaborative framework designed to make chemical research and development faster, more efficient, and more reproducible. Under the signed memorandum of understanding (MoU), the two companies will jointly explore automation-driven approaches to support new discoveries, particularly in the life sciences and electronics sectors.
Areas of Collaboration
According to the announcement, Merck and ChemLex will evaluate cooperation opportunities in the following areas:
-
automated chemical synthesis,
-
reaction optimization,
-
high-throughput experimental setups,
-
integration of chemistry platforms.
In the initial phase, the partners aim to identify programs with the potential to deliver “high impact” and to define concrete next steps for implementation.
Merck: “Accelerating digital transformation and innovation”
Marc Horn, President of Merck China, positioned the agreement as part of the company’s broader digitalization strategy in R&D. Horn stated:
“This strategic partnership with ChemLex demonstrates our commitment to embracing digital transformation and accelerating innovation by integrating artificial intelligence and automation into our R&D operations. Through this collaboration, we aim to create greater value for our customers.”
ChemLex: “A closed-loop system operating 24/7”
Dr. Sean Lin, Founder and CEO of ChemLex, highlighted the company’s AI-driven platform. Lin said:
“Our chemical synthesis platform, powered by artificial intelligence and equipped with a closed-loop feedback mechanism operating 24/7, is redefining the boundaries of synthesis efficiency. Deep collaboration with Merck China will provide an opportunity to validate and further develop our technology across a broader range of use cases.”
Both parties noted that this framework is intended to strengthen an approach centered on “scalable, data-rich experimental science” and to foster long-term partnerships at the intersection of chemistry and automation.
Source: prnewswire.com
